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Hypertension is one of the leading preventable risk factors in the 
global burden of disease,1,2 and its treatment reduces the risk of 
both stroke and coronary heart disease: a 10 mm Hg reduction in 
blood pressure (BP) is associated with a 41% and a 22% reduction 
in stroke and coronary heart disease, respectively.3 However, reg-
ular health surveys in a number of countries suggest that under-
diagnosis and undertreatment of hypertension are common.4–6
At present, hypertension is mainly detected through either 
opportunistic or routine systematic screening in primary care. 
However, both methods require attendance at primary care 
settings, which excludes individuals who do not routinely attend 
primary care, or those in whom routine screening is not practiced.
Community-based screening by non-physicians may pro-
vide an opportunity to increase routine detection of hyper-
tension in the community, outside of established healthcare 
organizations, and to target high-risk populations as well as 
those who do not attend primary care. Self-screening, where 
individuals measure their own BP, is now routinely avail-
able in a number of pharmacies, with some studies reporting 
large numbers of individuals using these facilities.7,8
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BACKGROUND
Community-based self-screening may provide opportunities to 
increase detection of hypertension, and identify raised blood pres-
sure (BP) in populations who do not access healthcare. This systematic 
review aimed to evaluate the effectiveness of non-physician screening 
and self-screening of BP in community settings.
METHODS
We searched the Cochrane Central Trials Register, Medline, Embase, 
CINAHL, and Science Citation Index & Conference Proceedings Citation 
Index—Science to November 2013 to identify studies reporting com-
munity-based self-screening or non-physician screening for hyperten-
sion in adults. Results were stratified by study site, screener, and the 
cut-off used to define high screening BP.
RESULTS
We included 73 studies, which described screening in 9 settings, 
with pharmacies (22%) and public areas/retail (15%) most commonly 
described. We found high levels of heterogeneity in all analyses, despite 
stratification. The highest proportions of eligible participants screened 
were achieved by mobile units (range 21%–88%) and pharmacies 
(range 40%–90%). Self-screeners had similar median rates of high BP 
detection (25%–35%) to participants in studies using other screeners. 
Few (16%) studies reported referral to primary care after screening. 
However, where participants were referred, a median of 44% (range 
17%–100%) received a new hypertension diagnosis or antihypertensive 
medication.
CONCLUSIONS
Community-based non-physician or self-screening for raised BP can 
detect raised BP, which may lead to the identification of new cases of 
hypertension. However, current evidence is insufficient to recommend 
specific approaches or settings. Studies with good follow-up of patients 
to definitive diagnosis are needed.
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The aim of this study was therefore to systematically review 
the evidence for self-screening and other community-based 
non-physician screening strategies, and the associated rates of 
target populations screened, detection of raised BP, and rates of 
follow-up and intervention, including new diagnoses, in pri-
mary care. A further aim was to establish the factors, such as 
appropriate settings, screeners, and targeted populations that 
underpin a successful screening program for hypertension. 
We considered that a successful screening program would 
obtain good coverage of the targeted population, and refer all 
new cases of screen-detected high BP for definitive diagnosis 
without excessive numbers of false-positive referrals.
METHODS
Search strategy
We searched the Cochrane Central Register of Controlled 
Trials (Issue 4 2011), Medline (from 1948), Embase (from 1974), 
CINAHL (from 1980), and Science Citation Index & Conference 
Proceedings Citation Index—Science (from 1945)  from the 
start of each database until 25th November 2013 using a search 
strategy developed with the assistance of an information spe-
cialist. The search strategy included terms relating to BP meas-
urement, community sites and screeners, and self-screening 
(Supplementary Appendix A). We subsequently added an 
exclusion criterion for studies conducted prior to 1980, as initial 
screening confirmed that suitable devices for self-screening were 
not generally available before this date. Additional studies were 
identified by searching reference lists of included studies.
Inclusion and exclusion criteria
We included studies reporting self-screening or com-
munity-based screening by non-physicians of BP in adults 
≥18  years of age (Table  1). “Self-screening” included home 
measurement of BP for screening purposes, but not for diag-
nostic or monitoring purposes. Screening carried out by 
clinically trained screeners (e.g., nurses) in clinical settings 
were excluded, although we included studies in community 
dentistry, as routine BP measurement is not usually practiced 
in community dentistry, and so this represents a novel set-
ting for BP screening. No limit by comparator or study design 
was applied. Studies where BP measurements were obtained 
during screening with the primary aim of detecting a condi-
tion other than hypertension, as well as those where multiple 
screening tests were performed in a single visit were included.
Study selection
Two authors (S.F. and H.A.) screened all titles and abstracts, 
and retrieved full text articles for potentially eligible studies. 
Where necessary, authors of studies were contacted up to 2 
times by electronic mail for clarification of inclusion status. 
If study eligibility could not be confirmed after 2 attempts to 
contact the authors, the study was excluded.
Data extraction
Data from each paper were extracted by one author (S.F., 
H.A., D.M., R.J.M., C.H., or A.W.), and the data extraction 
form checked by a second author in the group, with disagree-
ments resolved by consensus or a third author (S.F. or H.A.). 
Extracted data included study characteristics, the number 
screened, and where reported, the proportion eligible for 
screening, the proportion with screen-detected hyperten-
sion, the hypertension threshold used, the proportion with 
existing hypertension, and any follow-up carried out.
Assessment of quality
Quality assessment was conducted using criteria based 
on the Quality Assessment tool for Diagnostic Accuracy 
Studies-2 (QUADAS-2) at the same time as extraction, and 
by the same authors, with disagreements resolved by con-
sensus or a third author (S.F. or H.A.).9 The criteria assessed 
applicability and bias due to patient selection, appropriate-
ness of patients and setting, method of BP measurement, 
the prespecification and appropriateness hypertension 
threshold, and blinding to preexisting hypertension status 
(Supplementary Appendix B).
Data synthesis
Characteristics of included studies were summarized, 
including the populations screened, setting, and aspects of 
study design (Supplementary Appendix C).
Table 1. Inclusion and exclusion criteria
Inclusion criteria:
•	 Self-screening	or	screening	in	community	settings,	including	
mass	screenings,	community	dentistry,	and	pharmacy-based	
screening
•	 Majority	of	participants	aged	over	18 years
•	 Blood	pressure	screening	performed	by	non-physicians,	
including	nurses,	medical	students,	dentists,	pharmacists,	and	
lay	people
•	 Reporting,	as	a	minimum,	either	numbers	screened	for	
hypertension,	or	numbers	found	to	be	hypertensive	following	
screening
Exclusion criteria:
•	 Home	blood	pressure	measurement	for	diagnostic	or	
monitoring	purposes
•	 Blood	pressure	screening	performed	by	qualified	physicians	
(studies	were	not	excluded	if	physicians	gave	postscreening	
advice	but	did	not	participate	in	blood	pressure	measurement)
•	 Screening	by	clinically	trained	personnel	(including	nurses)	in	
clinical	settings—community	dentistry	was	not	included	in	this	
definition	of	a	clinical	setting
•	 Screening	of	employees	in	workplace	or	military	settings
•	 Studies	where	all	participants	had	an	existing	hypertension	
diagnosis
•	 Studies	of	established	research	cohorts	(including	those	using	
hypertension	screening	as	a	recruitment	tool)
•	 Studies	of	groups	identified	by	stratified	or	other	sampling	
methods	intended	for	use	in	epidemiological	studies
•	 Studies	carried	out	in	low-income	or	lower-middle	income	
countries,	as	defined	by	the	World	Bank
•	 Studies	published	before	1980
•	 Studies	published	in	a	language	other	than	English
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Data on the proportion of participants screened, and the 
proportion with high screening BP were reported grouped 
by the hypertension threshold defined in the study, size of 
study (number screened), qualification of person conduct-
ing the screening, and type of setting.
High levels of data heterogeneity meant that statistical 
synthesis was not possible. However, where at least 3 simi-
lar studies were included, their results were summarized 
using a box and whiskers plot, and possible factors relating 
to outliers discussed. We defined outliers as values further 
than 1.5 interquartile ranges from the nearest quartile.10 
Statistical analyses were carried out using R (version 3.0.1, R 
Foundation for Statistical Computing).
RESULTS
We identified 16,356 studies (Figure  1). After initial 
screening of titles and abstracts, we examined 285 full text 
papers, of which 73 met our inclusion criteria.
Characteristics of included studies
An overview of the variation in study design and loca-
tion is given in Table 2. Where reported (18 out of 73 stud-
ies, 25%), age of participants varied from a mean age of 
41–75  years. Several studies targeted specific populations; 
for example, 14 studies screened ethnic minority popula-
tions, and 2 screened men.
Screening was conducted in 9 different types of setting 
(Table 2). The majority of studies reporting data on the num-
ber of screening sites used (n = 29 out of 49 studies reporting 
these data, 59%) described between 1 and 5 screening sites.
The most frequently reported types of people perform-
ing the screening were nurses (n  =  17, 23%), followed 
by lay screeners (n  =  16, 22%), and only 3 studies used 
self-screening (Table 2). Only 39 (53%) studies reported 
the type of BP measurement device used, which included 
automated devices in 25 (34%) studies, and a manual 
sphygmanometer in 14 studies (19%). The number of 
measurements taken on each occasion was reported by 27 
studies and ranged from 1 to 12. If more than one BP was 
taken there was significant variation in the timing of sub-
sequent measurements.
Quality assessment
The results of the quality assessment (Figure  2) showed 
that few studies reported blinding to existing hypertension 
status (Supplementary Appendix D). Many studies (62%) 
were assessed as vulnerable to bias due to their recruitment 
Figure 1. Flow chart.
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methods, such as convenience sampling. The method for 
measuring BP was also poorly reported in the majority of 
studies, although most studies prespecified an appropriate 
threshold for hypertension.
Proportion of eligible participants screened
Twenty-three studies reported data for both the eligi-
ble population and the number screened, allowing the 
coverage of the screening strategies to be calculated. 
There was considerable heterogeneity both between and 
within sites (Figure 3): for example, 5 studies conducted in 
community buildings found that 12%–89% of eligible peo-
ple were screened. A similar range was noted for screen-
ers: for example, where nurses performed the screening, 
the proportion screened ranged from 5.5% to 99%. Mobile 
units (range 21%–88%) and pharmacies (range 40%–91%) 
achieved relatively high coverage across a range of stud-
ies. Some of the observed heterogeneity in coverage can 
be explained by differences in how eligible participants 
were defined in different studies. For example, 3 studies 
conducted in public areas and retail sites found that 5.5%–
97% of eligible people were screened, the main differences 
being whether the population at large or the population 
Table 2. Overview	of	study	designs
Characteristics Subgroups Number (%)
Location	of	study North	America 49	(67.1)
Europe 19	(26.0)
Australasia 4	(5.5)
Asia 1	(1.4)
Setting Pharmacies 16	(21.9)
Public	area/retail 11	(15.1)
Community	building	(e.g.,	fire	stations,	places	of	worship) 10	(13.7)
Mobile	unit 10	(13.7)
Home 8	(11)
Dental 7	(9.6)
Mixed	(multiple	settings	used	within	one	study) 7	(9.6)
Health	fair 3	(4.1)
Health	center	(screening	by	lay	person	or	self-screening) 1	(1.4)
Screeners Nurses 17	(23.3)
Lay	screeners 15	(20.5)
Pharmacy 11	(15.1)
Other	healthcare	professional	(e.g.,	paramedics,	
phlebotomists)
10	(13.7)
Dental 8	(11.0)
Mixed	(e.g.,	nurses	and	lay	screeners) 5	(6.8)
Students 4	(5.5)
Self-screening 3	(4.1)
Method	of	recruitment Opportunistic	in	healthcare	(e.g.,	at	dental	appointments) 12	(16.4)
Media	and	advertising 12	(16.4)
Letter	or	personal	invitation 10	(13.7)
Opportunistic	outside	healthcare 9	(12.3)
Passing	trade 7	(9.6)
Poster	and	flyers 5	(6.8)
Door-to-door 4	(5.5)
Not	specified 14	(19.2)
Communication	of	results Verbally	to	participant 16	(21.9)
Written	to	participant 14	(19.2)
Referral 10	(13.7)
Written	to	participant	and	primary	care	provider 7	(9.6)
Not	specified 26	(35.6)
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attending a particular setting was defined as the denomi-
nator.11–13 Results also varied widely both within and 
between each type of screener. Student screeners achieved 
a low range of coverage (3.4%–36%), whereas pharmacy 
staff obtained higher coverage of the eligible population 
(56%–91%).
Figure 2. Visualization of quality assessment.
0.00 25.00 50.00 75.00 100.00
Proportion of eligible participants receiving blood pressure screening (%)
Frank, 2008
Ghouri, 2005
Shellman, 2000
Marshall,  2013
Brunt, 1992
Engstrom, 2001
Johnson, 1984 (health centre)
Westerman, 1990
Johnson, 1984 (LC door−to−door)
Willis, 2012
Johnson, 1984 (HC door−to−door)
Agarwal, 2013
Carrington, 2009b
Diaz−Perez, 2004
Hill, 2012
Holmen, 1991
Cavaco, 2010
Huckerby, 2006
Hampton, 1990
Jones,  2008
Victor, 2011 (control arm)
Victor, 2011 (intervention arm)
Nugent, 1980
Carrington, 2010
Harris, 2011
Jacobsen, 1992
Community building
Community building
Community building
Community building
Community building
Dental
Health centre
Health centre
Home
Home
Home
Home
Mobile unit
Mobile unit
Mobile unit
Mobile unit
Pharmacy
Pharmacy
Pharmacy
Pharmacy
Public area / retail
Public area / retail
Public area / retail
Public area / retail
Mixed
Mixed
Nursing
Nursing
Nursing
Dental
Nursing
Dental
HCP
HCP
Students
Students
Students
HCP
HCP
HCP
HCP
Nursing
Pharmacy
Pharmacy
Pharmacy
Lay
Lay
Lay
Lay
Nursing
Nursing
Nursing
55
99
168
580
811
1149
20
1571
24
80
107
240
221
1098
2834
74977
51
70
70
406
2021
2655
2726
13825
2420
8612
61.80 [ 51.70 , 71.89 ]
30.94 [ 25.87 , 36.00 ]
12.09 [ 10.37 , 13.80 ]
74.84 [ 71.78 , 77.89 ]
88.73 [ 86.68 , 90.78 ]
64.15 [ 61.93 , 66.38 ]
 3.06 [  1.74 ,  4.38 ]
47.58 [ 45.87 , 49.28 ]
 3.43 [  2.08 ,  4.78 ]
36.36 [ 30.01 , 42.72 ]
20.42 [ 16.97 , 23.87 ]
85.71 [ 81.62 , 89.81 ]
27.73 [ 24.62 , 30.84 ]
70.70 [ 68.44 , 72.97 ]
21.35 [ 20.66 , 22.05 ]
88.10 [ 87.89 , 88.32 ]
91.07 [ 83.60 , 98.54 ]
56.00 [ 47.30 , 64.70 ]
58.33 [ 49.51 , 67.15 ]
39.80 [ 36.80 , 42.81 ]
96.70 [ 95.93 , 97.46 ]
88.38 [ 87.24 , 89.53 ]
13.94 [ 13.46 , 14.43 ]
 5.53 [  5.44 ,  5.62 ]
98.74 [ 98.29 , 99.18 ]
82.04 [ 81.31 , 82.78 ]
Paper
Number
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Range:  12.09 − 88.73 %
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Figure 3. Proportion of eligible participants receiving screening, ordered by site.
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Detection of hypertension in screened participants
Fifty-nine studies contained sufficient data to calculate the pro-
portion of screened participants who had hypertension. Although 
the definition of hypertension varied considerably between stud-
ies, there did not appear to be any relationship between hyperten-
sion threshold and detection rate (Supplementary Appendix F).
Most studies, whether grouped by site or screener, 
showed considerable heterogeneity in detection rate. 
Two types of site appeared to have lower detection rates: 
dental sites (range 8.5%–39%) and mobile sites (range 
3.2%–34%) (Supplementary Appendix G). A  number of 
the mobile sites served communities with reduced access 
to healthcare (e.g., immigrant communities in the United 
States).
It was notable that the 2 self-screening studies (i.e., 
those where participants measured their own BP)14,15 both 
resulted in detection rates (29% and 36%) comparable to 
the median detection rates seen in studies using a variety of 
other screeners (Figure 4).
One outlier study16 was found during the analysis, with 
considerably lower detection rates than the other studies 
carried out in pharmacies. This paper was relatively old 
and used considerably higher hypertension cut-offs than 
more contemporary work (variable with minimum cut-
off of 160/100 mm Hg), which would be expected to 
result in lower detection rates given a similar population.
Detection of hypertension in participants with and without 
preexisting diagnoses
Twenty-four studies provided data on detection of raised 
BP in participants with and without preexisting hyper-
tension diagnoses. Figure  5 shows that in many of these 
studies, the proportion of participants with uncontrolled 
hypertension (i.e., those with an existing hypertension diag-
nosis and a raised BP on screening) equaled or exceeded 
the proportion of potential new diagnoses (i.e., participants 
with raised BP on screening, but without any known diag-
nosis of hypertension). Most of these studies recruited from 
populations which were likely to be representative of the 
general population in the study area, rather than selected 
subgroups.
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42.47 [ 40.47 , 44.47 ]
39.74 [ 37.87 , 41.60 ]
 8.29 [  7.26 ,  9.33 ]
 5.97 [  5.18 ,  6.77 ]
60.57 [ 58.95 , 62.19 ]
13.30 [ 13.10 , 13.50 ]
47.27 [ 34.08 , 60.47 ]
13.13 [  6.48 , 19.78 ]
36.21 [ 29.07 , 43.35 ]
28.57 [ 22.13 , 35.01 ]
29.49 [ 23.43 , 35.56 ]
29.45 [ 24.62 , 34.27 ]
17.37 [ 14.43 , 20.31 ]
41.68 [ 38.28 , 45.07 ]
20.37 [ 18.77 , 21.98 ]
35.00 [ 34.20 , 35.80 ]
33.83 [ 33.04 , 34.62 ]
 3.20 [  3.07 ,  3.33 ]
32.56 [ 18.55 , 46.56 ]
39.53 [ 24.92 , 54.15 ]
58.82 [ 45.32 , 72.33 ]
28.57 [ 17.99 , 39.15 ]
31.00 [ 20.17 , 41.83 ]
 6.05 [  2.86 ,  9.23 ]
46.90 [ 40.87 , 52.93 ]
13.99 [ 10.02 , 17.97 ]
53.24 [ 47.53 , 58.96 ]
61.54 [ 56.45 , 66.63 ]
20.00 [ 15.97 , 24.03 ]
19.08 [ 15.20 , 22.97 ]
28.74 [ 25.54 , 31.94 ]
36.00 [ 35.97 , 36.03 ]
20.83 [  4.59 , 37.08 ]
73.75 [ 64.11 , 83.39 ]
17.76 [ 10.52 , 25.00 ]
49.79 [ 43.45 , 56.13 ]
32.08 [ 26.46 , 37.70 ]
53.11 [ 50.06 , 56.16 ]
22.72 [ 20.56 , 24.89 ]
36.10 [ 35.89 , 36.32 ]
Paper
Hypertension Number
Definition Site Screener Screened Percentage with raised BP [95% CI]
Range:  8.50 − 38.60 %
Range:  9.90 − 70.00 %
Range:  5.97 − 60.57 %
Range:  3.20 − 47.27 %
Range:  6.05 − 61.54 %
Range:  17.76 − 73.75 %
Range:  22.72 − 53.11 %
Figure 4. Proportion of screened participants with raised screening blood pressure, ordered by screener.
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Follow-up of participants after screening
Twelve studies provided data on participants following 
screening (Supplementary Appendix E). Only 3/7 (43%) 
referred all participants with elevated screening BP to pri-
mary care, and in one case, as few as 26% of those screening 
positive were referred. Eight studies reported the outcome 
of the referral, with a median of 44% (range 17%–100%) of 
those referred receiving a new hypertension diagnosis or 
new antihypertensive treatment. In 6 out of the 8 studies, 
this proportion exceeding 40%.
DISCUSSION
The results of this review show that community screening 
of BP by non-physicians (including self-screening) appears 
effective for detecting raised BP at screening, and that where 
data exists for this outcome, high screening BP leads to a new 
diagnosis or treatment for hypertension in a median of 44% 
of those referred. However, given the large amount of hetero-
geneity between study designs, it was not possible to carry 
out meta-analyses. Combined with the large amounts of vari-
ability in results between studies, this makes it difficult to 
recommend an optimal approach or setting. However, given 
the likely lower cost of self-screening compared to screening 
using nurses and other healthcare professionals, it is notable 
that self-screening appears to detect a similar proportion of 
participants with high BP as other screening strategies.
While many patients with existing hypertension may use 
community screening facilities, this is not necessarily a con-
cern, particularly given the proportion of treated patients 
with uncontrolled BP.6 Raised pressure in treated hyperten-
sives may prompt them to seek further appropriate medical 
care. Clear pathways for the referral and follow-up of patients 
identified with increased BP at screening are essential if 
the diagnosis of hypertension is to be established and any 
management benefits realized, but few studies reported any 
aspect of such follow-up. In many cases, raised screening BP 
was not subsequently acted upon, with only 3 out of 7 studies 
evaluating a system with universal referral of all such par-
ticipants. Reassuringly, where participants were referred and 
subsequently attended primary care, around 40% received 
an intervention (new hypertension diagnosis or antihyper-
tensive therapy), indicating the value of follow-up.
Considerable heterogeneity was observed across all analy-
ses, despite stratification, precluding formal meta-analysis. 
The remaining heterogeneity likely reflects differences in the 
underlying study populations, and how well these popula-
tions are able to access hypertension diagnosis and treat-
ment options. Additional potential sources of heterogeneity 
include methods of BP measurement, participant age range 
(which was typically poorly defined), and the influence of 
recruitment methods, some of which may have been more 
effective at targeting high-risk populations.
Blinding to existing hypertension status was poorly 
reported, but other than self-screening, there are no meth-
odological barriers to blinding observers to this outcome. 
Although a lack of blinding would not be a significant con-
cern for studies using automated devices, many studies in 
the review used manual BP measurement, which is known 
to be subject to terminal digit preference, and so observer 
bias may have been an issue for some of these studies where 
blinding was not present.17,18
The majority of studies (39, 53%) were undertaken in 
the United States. We may have missed studies from other 
countries; however, we did screen over 16,000 studies, and 
examined 285 full text papers. This suggests a lack of gener-
alizability of our findings to other countries, as the effects of 
Figure 5. Proportion of screened participants with and without preexisting hypertension diagnoses found to have high screening blood pressure.
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screening may be dependent on the organization and cover-
age of the healthcare system.
No previous systematic reviews of community screening or 
self-screening for hypertension were identified in the search 
results, suggesting that this paper provides the first comprehen-
sive review of the literature on this subject. International commu-
nity-based surveys of BP and hypertension prevalence continue 
to suggest both significant proportions of undetected hyperten-
sion and of poor control among those detected.19
The quality of the studies we found limits our ability to come 
to a definite conclusion as to the best method for implement-
ing hypertension screening. We therefore perceive the need 
for high-quality studies that include BP target definitions, 
measurement methods, and subsequent data on the propor-
tion of new hypertensive patients diagnosed. Indeed, those 
implementing self-screening should routinely embed a robust 
evaluation to underpin the ongoing use of resources in this 
area. To ultimately determine the cost effectiveness of these 
methods, there will be a need for robust randomized trials.
New developments in technology, including the use of 
social media to promote screening, use of smartphones, and 
enhanced network connectivity enabling screening results 
to be incorporated directly into electronic medical records, 
may improve the uptake and efficacy of community BP 
screening, and particularly self-screening.20
As few studies followed up all participants to diagnosis, 
we are unable to assess what proportion of participants with 
raised BP at screening had true hypertension. The lack of 
studies with adequate follow-up make it currently impos-
sible to determine whether these initiatives are effective or 
worthwhile. Properly powered studies including both cost 
and efficacy data are therefore required. As with standard 
clinical practice, such studies should follow-up all cases of 
raised BP with robust diagnostic methods.
In conclusion, despite a large number of studies report-
ing community-based BP screening by non-physicians, the 
evidence base for its effectiveness is very poor. Detection of 
high screening BP by self-screening is similar to that of more 
resource-intensive methodologies to identify participants 
with high BP, but cannot currently be recommended due to 
a paucity of data on this methodology.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American Journal 
of Hypertension (http://ajh.oxfordjournals.org).
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